Streetbeat News

ABCL

AbCellera Biologics Inc.

https://www.abcellera.com

Industry

Biotechnology

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Several top Wall Street analysts have downgraded their ratings for notable companies, including Globant S.A., Stride, Inc., AvidXchange Holdings, Inc., PropertyGuru Group Limited, and AbCellera Biologics Inc. Despite the downgrades, some companies saw an increase in their price targets.

Portfolio Pulse from Avi Kapoor

August 20, 2024 | 1:45 pm

Benchmark analyst Robert Wasserman has downgraded AbCellera Biologics (NASDAQ:ABCL) from a Buy to a Hold rating.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 11:40 am

AbCellera Biologics (NASDAQ:ABCL) reported Q2 EPS of $(0.13), beating the $(0.14) estimate, but missed sales estimates with $7.32M against $10.15M. EPS improved by 7.14% YoY, but sales decreased by 27.18%.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:07 pm

AbCellera (NASDAQ:ABCL) and Eli Lilly (NYSE:LLY) have expanded their collaboration to develop therapeutic antibodies for immunology, cardiovascular disease, and neuroscience. This builds on their successful partnership since March 2020, which included eight de novo programs and a COVID-19 antibody program that received emergency use authorization from the FDA.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:11 pm

Keybanc analyst Scott Schoenhaus maintains an Overweight rating on AbCellera Biologics (NASDAQ:ABCL) but lowers the price target from $8 to $7.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 6:18 pm

AbCellera Biologics reported Q1 2024 earnings with a GAAP EPS of $(0.14), surpassing the $(0.16) estimate. However, their sales of $9.954M fell short of the $10.836M estimate, marking an 18.36% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 8:13 pm

AbCellera (NASDAQ:ABCL) presented new data on its T-cell engager (TCE) programs at AACR 2024, showcasing advancements in cancer therapy. The data highlighted TCEs with potent tumor-cell killing and low cytokine release for targets like PSMA, B7-H4, and 5T4, and costimulatory CD28-binding antibodies enhancing T-cell activation without toxicity. Additionally, AbCellera is expanding TCE target space with high specificity for MAGE-A4-pMHC. These developments position AbCellera to advance TCEs as a drug class, potentially improving efficacy and safety for solid tumor treatments.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 4:06 pm

AbCellera and Biogen Inc. have announced a strategic collaboration to discover antibodies for a novel target that could enable the delivery of biotherapeutics to the brain, focusing on neurological conditions. AbCellera will receive an upfront payment and may also receive additional milestone payments and royalties on future net sales of products arising from this collaboration.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 1:03 pm

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:05 pm

AbCellera Biologics shares are trading lower following the announcement of mixed Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 3:52 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.